Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

With sales of its top-selling product, blood thinner Xarelto, tumbling because of generic competition, Bayer isn’t projecting growth for the pharma division until 2027. Bayer’s pharma sales ...

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

The crop-science plan announced Wednesday adds to those strategic priorities. Bayer faces fading earnings of blockbuster blood-thinning drug Xarelto, which is under pressure from generic competition ...

Bayer's diversified portfolio and robust late-stage pharmaceutical pipeline are expected to stabilize revenues despite LoE concerns, particularly with Xarelto facing generic competition.

Bayer AG BAYRY reported fourth-quarter 2024 core earnings of 28 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimates. The company reported earnings of 50 cents per ...

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto.

Taking the helm in mid-2023, Anderson inherited costly U.S. litigation over disputed claims that Bayer's weedkiller glyphosate causes cancer. Later that year, a once-promising blood thinner flopped in ...

The US Food and Drug Administration (FDA) has approved the first generics of Xarelto (rivaroxaban), a cardio vascular drug ...

J&J – which jointly developed Xarelto with Bayer – has US commercial rights to the drug and sells it as 2.5mg, as well as 10mg, 15mg, and 25mg tablets, along with a 1mg/ml oral suspension ...

The Food and Drug Administration (FDA) has approved the first generics of Xarelto ® (rivaroxaban) 2.5mg. Xarelto 2.5mg is used, in combination with aspirin, to: Reduce the risk of major cardiovascular ...